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Abstract  
Background: Reasons underlying time changes in cutaneous melanoma mortality in light-
skinned populations are not well understood. An analysis of long-term time trends in 
melanoma mortality was carried out after regrouping countries in homogeneous regions.  
Methods: Using the WHO mortality database, age-period-cohort models were fitted for 
seven regions where the majority of population is light-skinned. Cohort effects are denoted 
as changes in rates occurring at different time in steadily older age groups. Period effects are 
denoted as changes in rates occurring simultaneously in several age groups. 
Findings: Cohort effects better explained changes in melanoma mortality over time than 
period effects. Lifetime risk to die from melanoma increased in successive generations from 
1875 until a peak year. Peak years were for subjects born in 1936-40 in Oceania, 1937-43 in 
North America, 1941-42 in Northern Europe, 1945-53 in UK and Ireland, 1948 in Western 
Europe, and 1957 in Central Europe. After peak years, lifetime risk of melanoma death 
gradually decreased in successive generations and risks of subjects born in 1990-95 were 
back to risk levels observed for subjects born before 1900-05. In Southern Europe, birth 
years with highest lifetime risk of melanoma death have not yet been attained. As time 
passes, melanoma deaths will steadily rarefy in younger age groups and concentrate in older 
age groups, for ultimately fade away after 20430-540.  
Interpretation: Independently from screening or treatment, over next decades, death from 
melanoma is likely to become an increasingly rare event. The temporary epidemic of fatal 
melanoma was most probably due to the medically-backed practice of exposing unclothed 
children to intense natural and artificial sources of ultraviolet radiation that prevailed in 
1900-1960. The temporary epidemic of fatal melanoma was most probably due to excessive 
UV-exposure of children that prevailed in 1900-1960, and recent mortality decreases would 
be due to progressive reductions in UV-exposure of children over the last decades.  
 
Funding: This work was financed by the International Prevention Research Institute, Lyon, 
France. 
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Introduction  
The cutaneous malignant melanoma (hereafter termed melanoma) is the deadliest form of 
skin cancer. From 1955 to around 1985, melanoma death rates have more than doubled in 
all light-skinned populations. After 1985-1990, less steep increases or stabilizations, and 
even decreases in melanoma mortality rates have been observed in Australia,
1
 in the USA 
2
 
and in several European countries
3-8
 after that changes in the age distribution of populations 
over time had been controlled for in statistical analyses. However, understanding reasons 
possibly underlying time variations in the death toll due to melanoma is quite challenging 
when one looks more closely at the age at which these deaths occurred. For instance, in 
Northern Europe  (i.e., Denmark, Finland, Iceland, Norway, Sweden), before 1970, a minority 
of melanoma deaths occurred in subjects aged 70 or more while after 1995 in men and 1985 
in women, melanoma deaths were more numerous in this age group (Figure 1ab). Numbers 
of melanoma deaths in subjects less than 50 increased until around 1975, then stabilized and 
slowly decreased. Numbers of deaths in subjects aged 50 to 69 raised steeply until 1985-90, 
after which increases slowed down in men and death numbers plateaued in women. 
Comparable epidemiological features have been observed in all light-skinned populations 
(Figure S1). The contrasting time variations in melanoma death across age groups indicate 
that the influence of risk factors involved in the occurrence of deadly melanoma had varied 
over time and is independent from population ageing. Factors independent of ageing that 
influence disease burden over time are defined as period or cohort effects or a combination 
of both.
9
 Period effects are characterized by changes in mortality rates taking place at about 
the same time in several age groups, for instance after the offering of efficient screening 
program or treatment to subjects of different ages. Cohort effects are characterized by 
changes in mortality rates taking place in successive generations, for instance after 
introduction of prevention policies targeting children whose effect on mortality will be first 
observed in younger age groups and then progressively extend to older age groups.  
In order to better understand reasons underlying divergences in age-specific trends in 
melanoma mortality, we carried out an analysis of long-term time trends in melanoma 
mortality in countries where the majority of the population is light-skinned. The objective of 
our study was to disentangle the respective contributions of age at which melanoma death 
occurred, of population aging, of cohort effects, and of period effects. To this end, we 
regrouped countries by homogeneous geographical regions so that sufficient statistical 
power could be secured.  
Methods 
Mortality data 
Mortality data on melanoma were retrieved from the WHO mortality database (09/07/2012 
release). Data were extracted for countries mainly populated with light-skinned subjects. 
Annual data were obtained for each sex by 5-years age groups (from 0-4 years to 85 and 
more).  Melanoma mortality codes from the international classifications of diseases (ICD) 
were 190 for ICD7, 172 for ICD8, 172 for ICD9, C43 for ICD10. Data were available from 1955 
to 2010 in most countries. France was excluded of the analysis because of misclassification 
in melanoma/Non Melanoma Skin Cancer codes in the 1960s owing to problems in transition 
from ICD7 to ICD8 lists. In the USA, melanoma mortality data were not available for the 
1968-1978 period and we just estimated missing data by interpolation of data before 1968 
and data after 1978. 
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Grouping countries into regions 
In order to increase the statistical power of the analysis, countries were grouped into main 
regions of the world. Within each region, deaths and population by age group and sex were 
added. Countries were grouped as follows: 
x Oceania: Australia and New-Zealand 
x North America: Canada and the United States of America (USA) 
x Northern Europe: Denmark, Finland, Iceland, Norway, Sweden 
x United Kingdom and Ireland 
x Western Europe: Austria, Belgium, Germany (former German Democratic Republic 
and former Federal Republic of Germany  1980-1989; Reunified Germany since 
1990), the Netherlands and Switzerland 
x Central Europe: Bulgaria, the Czech Republic, Estonia, Hungary, Latvia, Poland, 
Romania, Slovakia and Slovenia 
x Southern Europe: Greece, Italy, Portugal and Spain 
Statistical analysis 
Age standardisation 
Mortality rates were age-standardized by the direct method using Segi World standard 
population
10
 as reference.  
Joinpoint Modelling 
Time changes in the age-standardized rates were modeled using joinpoint version 
3.5.0 (Joinpoint Regression Program, Version 3.5 - April 2011; Statistical Methodology and 
Applications Branch and Data Modeling Branch, Surveillance Research Program National 
Cancer Institute). Joinpoint enables to model several regression lines connected by 
joinpoints at which significant inflexion could be detected; the program reports the simplest 
model that the data allow. Log-linear models were used in the analysis of trends and the 
identification of 0 to 3 joinpoints to either end of the data were allowed. The minimum 
number of allowed datapoints between joinpoints was 4. 
This time-trend modeling approach enables to provide an evaluation of trends that is not 
user dependent as finding of joinpoints is data driven and identified through a series of 
permutation tests. Analyses were carried out for each region by sex and by age group (less 
than 50; 50 to 69 and more than 70). 
Age-period-cohort modelling 
Age-period-cohort (APC) models were fitted to mortality data using R 3.0.1. More precisely, 
the function apc.fit from the Epi 1.1.67 package 
11
 was used. To solve the problem of 
identifiability in such models,
9
 a penalty function was applied to period effects which 
constrained the average period effect to be null with a null slope. The analysis was repeated 
applying the same penalty function to the cohort effect. The two ways to parameterize data 
led to similar results (data not shown).  
The analysis was repeated applying the same penalty function to the cohort effect. Applying 
the penalty function to the period effect or to the cohort effect resulted in similar changes in 
deviance (data not shown). 
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Subjects less than 15 were excluded from analyses. In results, cohorts were identified by 
their middle-year. Because first and last years of available data on causes of death could vary 
between countries, or because of missing years, study periods were restricted to 5-year 
groups for which complete data were available. The reference cohort, noted 1935, 
corresponds to people born between the 1
st
 of January 1933 and the 31
st
 of December 1937. 
The year 1935 was selected because in all regions, it was approximately the median birth 
cohort of subjects who died from melanoma. Results from APC models included age-specific 
effects, cohorts and period effects reported as relative risk with a reference cohort set to 
1935 (RR=1·0).  
Results 
Detailed results for Northern Europe are presented first after which main results for all 
regions are provided with complete results displayed in the supplementary materials. 
Northern European countries 
Mortality rates in Figure 1cd are the numbers of melanoma deaths displayed in Figure 1ab 
divided by numbers of men or women of each age group in given year, followed by age 
standardization on the Segi World Standard Population.
10
 Hence trends in Figures 1cd are 
independent of population aging. Time trends were derived from join point analyses that 
quantified percent changes in mortality rates during a specific time period and detected 
years during which statistically significant changes in trends were noticeable (Table S1). 
Overall, melanoma mortality was still rising in the 2000s with annual percent changes of 
2.47% (95% CI: 0.91; 4.05) in 2002-10 in men and of 1.53% (95% CI: 0.73; 2.34) in 1996-2010 
in women. However, Iin men and women less than 50, an abrupt reversal in trends took 
place in 1970-71, while . Iin men and women 50-69, trends stabilized after 1983-84. , while 
iIn men and women aged 70 and more, trends have risen without interruption from 1955 to 
2010.  
 
A more refined examination of trends specific to each 10-year age group show that the 
younger the men and women, the earlier the stabilization or start of declines in trends 
(Figure 1ef). For each increment in 10-year age group, there was a 6 to 8 years shift of the 
year from which rates started to stabilize. Downward trends in years after the stabilization 
were observed for men and women less than 50, but not yet for the 50-59 and 60-69 age 
groups. Above 69 years of age, melanoma mortality rates continued to rise. A subject aged 
70 in 2010 was born in 1940. Hence the risk of melanoma death has leveled off in successive 
generations of subjects born after 1940, which is the hallmark of cohort effects. Because in 
2010, subjects born after 1940 have not yet reached 70 years of age, stabilization of 
mortality rates are not yet visible in subjects aged 70 and more.  
Instead of examining trends according to calendar years, one can examine trends according 
to years of birth (Figure 1gh). Each curve reflects changes in mortality rates specific to 10-
year age groups whose subjects were born at different epochs. The vertical dashed line 
indicates that trends in melanoma mortality stabilized and then declined in successive 
cohorts of men born after 1940-45. Rates will continue to decline in cohorts of subjects less 
than 70 born after 1940. It is highly likely that in coming years, rates in subjects aged 70 or 
more born after 1940-45 will progressively stabilize and then decline.  
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From age-period-cohort analyses, we could quantify the influence of cohort and period 
effects on time trends of melanoma death through an examination of the residual deviance 
of models that is the amount of variation in mortality data not explained by a model. 
Analysis of deviance comparing the five classical models (Age, age-drift, age-cohort, age-
period and age-period-cohort) are reported in Table S2. The residual deviance was smaller 
for age-cohort models than for age-period models, indicating that changes in melanoma 
mortality over time were better explained by cohort effects than by period effects. 
Therefore, the remaining of the text will focus on results from age-period-cohort models 
with penalty function applied to the period effect.  
Birth cohort effects can be summarized as the risk to die from melanoma when born at a 
certain year relative to a reference year (1935) for which the risk is arbitrarily set to 1·0 
(Figure 1ij).  Peak years for highest risk of melanoma death were observed in men born 
around 1942 and in women born around 1941. The relative risk of melanoma death of men 
born before 1885 was less than 0·25, i.e., less than 25% the risk of melanoma death of men 
born around 1935. The relative risk of women born before 1885 was 30% the risk of 
melanoma death of women born around 1935. After 1941-42, risks declined without 
interruption. The risk of melanoma death of men and women born around 1990 was similar 
to the risk of men and women born around 1900. 
Because of cohort effects, as time passes, melanoma deaths concentrate in older age groups 
and become steadily rarer in younger age groups (Figure 1kl). Independently from 
population aging, in 1955-59, 30% of melanoma deaths in men occurred before age 50, 40% 
of deaths occurred between 50 and 69, and 30% occurred after 69. From 2005 to 2010, 10% 
of melanoma deaths in men occurred before age 50, 40% of deaths occurred between 50 
and 69, and 50% occurred after 69. Comparable changes were observed in women.  
Results for other regions 
Similarly to Northern Europe, age-adjusted melanoma mortality rates stabilized and then 
declined in subjects less than 50, raising trends slowed down or stabilized in subjects 50 to 
69, and kept increasing in subjects 70 years or more (Figure S2). If from 2000 to 2010 annual 
percent changes for all age groups still indicated still raising melanoma mortality, principally 
in Europe (Table S1), this was largely due to the demographic weight of older subjects who 
experienced unabated raising trends in melanoma mortality. Hence, trends were mainly 
explained by cohort effects, and with few exceptions, the residual deviance of age-cohort 
models was smaller than that of age-period models (Table S2).  
Figure 2 shows the lifetime risk of melanoma death for each birth year in a region relative to 
rates in that region observed in the birth cohort centered around 1935. Relative risks are to 
be interpreted for each region, and not between regions. Contrasts in trends between 
regions are the consequence of variations in peak birth years associated with highest risk of 
melanoma death. In all regions, the risk of melanoma death in men was minimal for men 
born before 1880. Then risks sharply increased, reaching a peak for men born in 1940 in 
Oceania, 1943 in North America, 1942 in Northern Europe, 1948 in Western Europe. After 
the peak years, the lifetime risk of dying from melanoma has gradually decreased among 
successive birth years. In Central Europe, a similar birth cohort pattern was observed, but it 
was delayed by 10-15 years. Of note, age-specific levels and changes in melanoma mortality 
rates in Western and in Central Europe are practically superimposable.  
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In general, lifetime risk patterns in women resembled to those seen in men, with closeness 
between sexes of birth years for which the risk of melanoma death was highest. In the 
Ireland and United Kingdom region, it took until 1995 before the lifetime risk of melanoma 
death in men came back to risk levels of men born around 1935. In Southern Europe, in both 
sexes, the birth years after which the risk to die from melanoma would decrease have not 
yet been reached, although in women less than 50, first signs of decreases are noticeable in 
recent years (Figure S3). 
As a consequence of cohort effects, in most regions, stabilization and then declines in 
mortality rates progressively extended from younger to older age groups (Figure S3). This 
process is most advanced in Oceania and in North America, where first signs of leveling off 
and declines of rates in subjects more than 69 years of age are perceptible. In these two 
regions, trend in all ages have stabilized (men in Oceania) or are declining (women in 
Oceania and men and women in North America). In Western and Central Europe, mortality 
rates in all age groups have constantly risen but stabilization and declines in subjects less 
than 60 are discernible. In Southern Europe, stabilization of trends is perceptible over the 
recent past among subjects less than 50. In Ireland and United Kingdom, declines similar to 
those observed in women less than 50 were not yet visible in men of same age, which 
explains the persistence of a high risk of melanoma death in Irish and UK men born after 
1953.  
In all regions, independently of aging, melanoma deaths are progressively rarer in younger 
age groups and concentrates in subjects 50 years or more (Figures S4). 
Discussion  
Our study documented that variations in melanoma mortality rates over time were the 
result of substantial changes in the risk of melanoma death in successive generations. If after 
2000 melanoma mortality was still on the rise in some Regions, particularly in Europe, this 
was essentially the consequence of sustained rising trends in older age groups because in 
younger age groups, these trends had stabilized or had started to decline well before 1990. 
Because data on causes of death are available from 1955 onwards in the WHO mortality 
database, birth cohort effects could not be explored for subjects born before 1875. 
However, probably that increasing lifetime risk of melanoma death was already present 
among subjects born before 1875.
12
 Peak years of risk were reached for subjects born 
around 1936-43 in Oceania, North America and Northern Europe, around 1948 in Western 
Europe, 1945-53 in the United Kingdom and Ireland and around 1957 in Central Europe. 
After peak years, steady reductions in mortality risks took place in successive generations. 
Over next decades, generations with gradually lower risk of lifetime melanoma death will 
replace generations that had higher lifetime risk of melanoma death. We thus expect that 
over coming decades, melanoma mortality will stop rising, stabilize and then decline in all 
light skinned populations. First signs of declines should be observed in Oceania and in 
Northern America, and lastly in Southern Europe. 
However, if dying from melanoma is deemed to become a steadily uncommon event in 
younger and middle-aged adults, population aging will keep numbers of patients diagnosed 
with potentially fatal melanoma at a high level over the next two decades because the risk of 
melanoma death in men and women born around 1940 to 1950 is still high. After 2030, 
numbers of melanoma deaths are likely to progressively vanish when subjects born from 
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1970 onwards who have a low risk of melanoma death will reach their six or seventh decade 
of life.  
A number of studies already indicated long-term declines in melanoma mortality starting in 
youngest age groups and progressively extending to older age groups.
1,12-14
 The principal 
strengths of our study iswere that we compared groups of countries populated with a 
majority of light-skinned subjects, and data we the used of data were collected over longer 
periods than in previous studies. Also, assembling data by region increased the statistical 
power, which contributed to greater accuracy in estimations of statistical parameters related 
to age, cohort and period effects. Limitations of our study were the absence of usable data 
for France and gaps in mortality data for some years like in the USA. Also, some countries 
brought corrections to their data, which might explain inconsistencies in trends like in 
Central Europe before 1970 (Figure S2f). 
SEE THE NEW DISCUSSION IN THE REVISED MS, CLEAN VERSION 
Could changes in melanoma mortality trends reflect the effect of treatment and of skin 
screening (including occasional removal of brown spots to periodical full body skin 
examination)? The predominance of cohort effects over period effects we found in our study 
argues against screening and treatment effects. If effective screening or treatment had 
existed since the 1980s, their impact on melanoma mortality rates would have affected 
several age groups at about the same time (period effect). Effective treatment exist only 
since 2010 and are not yet associated with long-lasting disease remission. For screening, first 
effects should have been observed in women 30 to 50 because this gender and age group is 
more inclined to attend skin screening. In addition, the purpose of skin screening is to detect 
melanoma before they have become thick with the possibility of metastases in lymph nodes 
or in distant organs. If skin screening was effective, downward mortality trends should be 
preceded by decreases in the incidence of tick melanoma. However, stable or steady 
increase in the incidence of thick melanoma are observed in virtually all fair-skinned 
populations (Ambrosini-Spaltro et al., 2014; Bordoni et al., 2013; Downing et al., 2006; 
Hollestein et al., 2012; Jemal et al., 2001; Lasithiotakis et al., 2006; Lipsker et al., 1999; 
MacKie et al., 2007; Marrett et al., 2001; Montella et al., 2009; Richardson et al., 2008; 
Tejera-Vaquerizo et al., 2008; van der Rhee et al., 1999; Whiteman et al., 2014). In subjects 
less than 50, , trends in thick melanoma are stabilizing or increase at a slower pace than in 
older subjects, but no data suggest declines in incidence of thick melanoma that would 
correlate with stabilization or declines in mortality trends in younger age groups (Baade et 
al., 2012; Jemal et al., 2011; Linos et al., 2009). Moreover, trends in thick melanoma remain 
stable or continue to increase in the USA and in Queensland (Australia)  despite notable 
increases in the in the prevalence of skin examinations and excisions, and in the incidence of 
in situ melanoma, a marker of skin screening intensity (Carrière; Coory et al., 2006; Geller et 
al., 2013; Welch et al., 2005).The predominance of cohort effects points to the 
epidemiological and experimental evidence that UV exposure during early life would be the 
most critical period for the occurrence of sun-induced biological events implicated in the 
genesis of melanoma (IARC, 1992). For instance, migrant studies have documented that the 
risk of melanoma occurrence or of death is two to three times greater among light-skinned 
subjects born in Australia than among subjects of European descent who migrated to 
Australia after 15 years (Khlat et al., 1992; Whiteman et al., 2001). Melanoma occurrence in 
adult life seems unlikely in the absence of sun exposure during childhood (Autier & Doré, IJC, 
1998(Autier et al., 1997)). Animal experiments have shown that susceptibility to UV-
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induction of melanoma is greatest just after birth (Noonan et al., 2001; Zaidi et al., 
2008)(Handoko et al, 2013). According to these data, some parallelism should exist between 
age-specific changes in melanoma incidence and mortality. Over the last three decades, 
increases in the incidence of invasive melanoma have been more marked than increases in 
melanoma mortality. Nonetheless, some evidence has recently emerged for stabilisation or 
decreasing trends in ŵŽƌĞƌĞĐĞŶƚůǇ ?ďŽƌŶĐŽŚŽƌƚƐŝŶƵƐƚƌĂůŝĂ ?EĞǁĞĂůĂŶĚ ?ƚŚĞh ?^ ? ? ?
Canada and Norway (Erdmann et al., 2013).  
 
 
Taken altogether, these facts  indicate  that the ultraviolet radiation would be capable to 
cause the occurrence of deadly melanoma in adult life when exposure  takes place in early 
life. 
We therefore formulate the hypothesis that trends in melanoma mortality would be due to 
dramatic changes in exposure of small children to ultraviolet radiation, when in the second 
part of the 19
th
 century, beliefs in the healthiness virtues of the sun and of the ultraviolet 
radiation expanded among health professionals and large segments of the population 
(Albert et al., 2002; Albert et al., 2003; Hockberger, 2002; Holman et al., 1980). The 
popularity of exposing children to natural or artificial sources of UV would have been 
maximal around 1936 to 1957, depending on regions. The sun spectrum contained large 
amounts of UVA and UVB radiation and many artificial UV-emitting devices commercialized 
before 1960 emitted the full UV range, including the UVC, a wavelength present in the 
sunlight that is completely absorbed by the stratospheric ozone layer. At the time, there was 
complete ignorance about the deleterious effects of UV radiation. Starting in Oceania in the 
1970-80s, sun protection of children has become increasingly common with the recognition 
that sun exposure and sunburn experience during childhood causes irreversible damages to 
the skin and are strong risk factors for skin cancer in adult life (MacKie et al., 2009; Marks, 
1990). So, most probably that UV-exposure patterns of children associated with occurrence 
of deadly melanoma in adults have progressively disappeared in successive generations after 
1960. However, in Southern Europe, these exposure patterns seem to have appeared more 
recently. 
Long-term data on incidence of advanced melanoma going back to the 1970s and before are 
not available. However, the contrast between trends in the incidence of advanced 
melanoma and of melanoma mortality in younger age groups could be the sign of a 
progressive change in the disease biology, with melanoma being progressively less 
aggressive as one moves away from the peak birth years associated with highest risk of 
melanoma death. This hypothesis is supported by studies that examined the influence of 
year at diagnosis on risk of melanoma death over a fixed duration of follow-up (e.g., 5-year 
survival) and that took into consideration major predictors of melanoma patient 
survival.
30,37,38
 In these studies, the more recent the year of diagnosis, the better the 
survival. One study has suggested that vaccination against common infectious diseases in 
early life was associated with greater melanoma survival (Kolmel et al., 2005). One could 
speculate that increasing vaccination coverage after 1950 has induced immune-editing 
phenomena that have strengthened the capacity of the immune system to control 
potentially deadly melanoma. 
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The role of UV-exposure during adulthood on the risk of melanoma death remains unclear. 
One clue may proceed from Central European countries, where between 1945 and the 
1990s, political and economic circumstances limited possibilities of holidays in sunny 
climates. However, levels and trends in melanoma mortality in Central and in Western 
Europe were quite similar, apart from a 10-year difference in the start of declines. These 
similarities may be an indication that recreational UV exposure during adult life has probably 
less influence on the risk of melanoma death. Recreational and cosmetic UV exposure in 
adult life, together with increasing skin screening and variability in the classification of 
histologically equivocal lesions would contribute for most of the raising incidence of non-life-
threatening in situ or in thin invasive melanoma (Autier et al., 2011; Levell et al., 
2009)(Norgaard et al, 2011; van der Rhee et al, 2009).  
The strong association between aging and the risk of melanoma death suggests an interplay 
between accumulated sun exposure and the age-related decreasing capability of the 
immune system to control dormant cancer cells having considerable malignant potential 
(Shen et al., 2014). Probably that studies in adults should put the emphasis on factors 
altering the anti-cancer control functions of the immune system. In conclusion, over next 
decades, deaths due to melanoma in light-skinned populations will progressively 
concentrate in oldest subjects, and then progressively diminish for becoming an increasingly 
rare event.  
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Figure captions 
Figure 1  ? Time trends in cutaneous melanoma mortality in Northern Europe, 1955-2010 
(Denmark, Finland, Iceland, Norway, Sweden). Crude numbers of men (1a) and women (1b) 
who died from melanoma. Age-adjusted rates for men (1c) or women (1d) aged less than 50, 
50 to 69, and 70 or more. Age-specific rates for men (1e) or women (1f) by 10-year age 
group. Thick vertical bars indicate years of rate stabilization. Age-specific melanoma 
mortality rate according to year of birth of men (1g) and women (1h). Cumulative lifetime 
risk of melanoma death according to year of birth relative to the risk in men (1i) and women 
(1j) born around 1935. Age-adjusted proportions of melanoma deaths in men (1k) or in 
women (1l) less than 50, 50 to 69, and 70 or more.  
Figure 2 - Cumulative lifetime risk of melanoma death in regions according to year of birth 
relative to the risk in men and women born around 1935. 
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Abstract  
Background: Reasons underlying time changes in cutaneous melanoma mortality in light-
skinned populations are not well understood. An analysis of long-term time trends in 
melanoma mortality was carried out after regrouping countries in homogeneous regions.  
Methods: Using the WHO mortality database, age-period-cohort models were fitted for 
seven regions where the majority of population is light-skinned. Cohort effects are denoted 
as changes in rates occurring at different time in steadily older age groups. Period effects are 
denoted as changes in rates occurring simultaneously in several age groups. 
Results: Cohort effects better explained changes in melanoma mortality over time than 
period effects. Lifetime risk to die from melanoma increased in successive generations from 
1875 until a peak year. Peak years were for subjects born in 1936-40 in Oceania, 1937-43 in 
North America, 1941-42 in Northern Europe, 1945-53 in UK and Ireland, 1948 in Western 
Europe, and 1957 in Central Europe. After peak years, lifetime risk of melanoma death 
gradually decreased in successive generations and risks of subjects born in 1990-95 were 
back to risk levels observed for subjects born before 1900-05. In Southern Europe, birth 
years with highest lifetime risk of melanoma death have not yet been attained. As time 
passes, melanoma deaths will steadily rarefy in younger age groups and concentrate in older 
age groups, for ultimately fade away after 2040-50.  
Conclusion: Independently from screening or treatment, over next decades, death from 
melanoma is likely to become an increasingly rare event. The temporary epidemic of fatal 
melanoma was most probably due to excessive UV-exposure of children that prevailed in 
1900-1960, and mortality decreases would be due to progressive reductions in UV-exposure 
of children over the last decades.  
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Introduction  
The cutaneous malignant melanoma (hereafter termed melanoma) is the deadliest form of 
skin cancer. From 1955 to around 1985, melanoma death rates have more than doubled in 
all light-skinned populations. After 1985-1990, less steep increases or stabilizations, and 
even decreases in melanoma mortality rates have been observed in Australia,[1] in the USA 
[2] and in several European countries [3-8]. However, understanding reasons possibly 
underlying time variations in the death toll due to melanoma is quite challenging when one 
looks more closely at the age at which these deaths occurred. For instance, in Northern 
Europe  (i.e., Denmark, Finland, Iceland, Norway, Sweden), before 1970, a minority of 
melanoma deaths occurred in subjects aged 70 or more while after 1995 in men and 1985 in 
women, melanoma deaths were more numerous in this age group (Figure 1ab). Numbers of 
melanoma deaths in subjects less than 50 increased until around 1975, then stabilized and 
slowly decreased. Numbers of deaths in subjects aged 50 to 69 raised steeply until 1985-90, 
after which rates slowed down in men and plateaued in women. Comparable 
epidemiological features have been observed in all light-skinned populations (Figure S1). The 
contrasting time variations in melanoma death across age groups indicate that the influence 
of risk factors involved in the occurrence of deadly melanoma had varied over time and is 
independent from population ageing. Factors independent of ageing that influence disease 
burden over time are defined as period or cohort effects or a combination of both.[9] Period 
effects are characterized by changes in mortality rates taking place at about the same time 
in several age groups, for instance after the offering of efficient screening program or 
treatment to subjects of different ages. Cohort effects are characterized by changes in 
mortality rates taking place in successive generations, for instance after introduction of 
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prevention policies targeting children whose effect on mortality will be first observed in 
younger age groups and then progressively extend to older age groups.  
In order to better understand reasons underlying divergences in age-specific trends in 
melanoma mortality, we carried out an analysis of long-term time trends in melanoma 
mortality in countries where the majority of the population is light-skinned. The objective of 
our study was to disentangle the respective contributions of age at which melanoma death 
occurred, of population aging, of cohort effects, and of period effects. To this end, we 
regrouped countries by homogeneous geographical regions so that sufficient statistical 
power could be secured.  
Methods 
Mortality data 
Mortality data on melanoma were retrieved from the WHO mortality database (09/07/2012 
release). Data were extracted for countries mainly populated with light-skinned subjects. 
Annual data were obtained for each sex by 5-years age groups (from 0-4 years to 85 and 
more).  Melanoma mortality codes from the international classifications of diseases (ICD) 
were 190 for ICD7, 172 for ICD8, 172 for ICD9, C43 for ICD10. Data were available from 1955 
to 2010 in most countries. France was excluded of the analysis because of misclassification 
in melanoma/Non Melanoma Skin Cancer codes in the 1960s owing to problems in transition 
from ICD7 to ICD8 lists. In the USA, melanoma mortality data were not available for the 
1968-1978. 
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Grouping countries into regions 
In order to increase the statistical power of the analysis, countries were grouped into main 
regions of the world. Within each region, deaths and population by age group and sex were 
added. Countries were grouped as follows: 
x Oceania: Australia and New-Zealand 
x North America: Canada and the United States of America (USA) 
x Northern Europe: Denmark, Finland, Iceland, Norway, Sweden 
x United Kingdom and Ireland 
x Western Europe: Austria, Belgium, Germany (former German Democratic Republic 
and former Federal Republic of Germany  1980-1989; Reunified Germany since 
1990), the Netherlands and Switzerland 
x Central Europe: Bulgaria, the Czech Republic, Estonia, Hungary, Latvia, Poland, 
Romania, Slovakia and Slovenia 
x Southern Europe: Greece, Italy, Portugal and Spain 
Statistical analysis 
Age standardisation 
Mortality rates were age-standardized by the direct method using Segi World standard 
population [10] as reference.  
Joinpoint Modelling 
Time changes in the age-standardized rates were modelled using joinpoint version 3.5.0 
(Joinpoint Regression Program, Version 3.5 - April 2011; Statistical Methodology and 
Applications Branch and Data Modelling Branch, Surveillance Research Program National 
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Cancer Institute). Joinpoint enables to model several regression lines connected by 
joinpoints at which significant inflexion could be detected; the program reports the simplest 
model that the data allow. Log-linear models were used in the analysis of trends and the 
identification of 0 to 3 joinpoints to either end of the data were allowed. The minimum 
number of allowed data points between joinpoints was 4. 
This time-trend modeling approach enables to provide an evaluation of trends that is not 
user dependent as finding of joinpoints is data driven and identified through a series of 
permutation tests. Analyses were carried out for each region by sex and by age group (less 
than 50; 50 to 69 and more than 70). 
Age-period-cohort modelling 
Age-period-cohort (APC) models were fitted to mortality data using R 3.0.1. More precisely, 
the function apc.fit from the Epi 1.1.67 package [11] was used. To solve the problem of 
identifiability in such models[9], a penalty function was applied to period effects which 
constrained the average period effect to be null with a null slope.  
The analysis was repeated applying the same penalty function to the cohort effect. Applying 
the penalty function to the period effect or to the cohort effect resulted in similar changes in 
deviance (data not shown). 
Subjects less than 15 were excluded from analyses. In results, cohorts were identified by 
their middle-year. Because first and last years of available data on causes of death could vary 
between countries, or because of missing years, study periods were restricted to 5-year 
groups for which complete data were available. The reference cohort, noted 1935, 
corresponds to people born between the 1
st
 of January 1933 and the 31
st
 of December 1937. 
The year 1935 was selected because in all regions, it was approximately the median birth 
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cohort of subjects who died from melanoma. Results from APC models included age-specific 
effects, cohorts and period effects reported as relative risk with a reference cohort set to 
1935 (RR=1·0).  
Results 
Detailed results for Northern Europe are presented first after which main results for all 
regions are provided with complete results displayed in the supplementary materials. 
Northern European countries 
Mortality rates in Figure 1cd are the numbers of melanoma deaths displayed in Figure 1ab 
divided by numbers of men or women of each age group in given year, followed by age 
standardization on the Segi World Standard Population[10]. Hence trends in Figures 1cd are 
independent of population aging. Time trends were derived from joinpoint analyses that 
quantified percent changes in mortality rates during a specific time period and detected 
years during which statistically significant changes in trends were noticeable (Table S1). 
Overall, melanoma mortality was still rising in the 2000s with annual percent changes of 
2.47% (95% CI: 0.91; 4.05) in 2002-10 in men and of 1.53% (95% CI: 0.73; 2.34) in 1996-2010 
in women. However, in men and women less than 50, an abrupt reversal in trends took place 
in 1970-71, while in men and women 50-69, trends stabilized after 1983-84. In men and 
women aged 70 and more, trends have risen without interruption from 1955 to 2010.  
A more refined examination of trends specific to each 10-year age group show that the 
younger the men and women, the earlier the stabilization or start of declines in trends 
(Figure 1ef). For each increment in 10-year age group, there was a 6 to 8 years shift of the 
year from which rates started to stabilize. Downward trends in years after the stabilization 
were observed for men and women less than 50, but not yet for the 50-59 and 60-69 age 
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groups. Above 69 years of age, melanoma mortality rates continued to rise. A subject aged 
70 in 2010 was born in 1940. Hence the risk of melanoma death has leveled off in successive 
generations of subjects born after 1940, which is the hallmark of cohort effects. Because in 
2010, subjects born after 1940 have not yet reached 70 years of age, stabilization of 
mortality rates are not yet visible in subjects aged 70 and more.  
Instead of examining trends according to calendar years, one can examine trends according 
to years of birth (Figure 1gh). Each curve reflects changes in mortality rates specific to 10-
year age groups whose subjects were born at different epochs. The vertical dashed line 
indicates that trends in melanoma mortality stabilized and then declined in successive 
cohorts of men born after 1940-45. Rates will continue to decline in cohorts of subjects less 
than 70 born after 1940. It is highly likely that in coming years, rates in subjects aged 70 or 
more born after 1940-45 will progressively stabilize and then decline.  
From age-period-cohort analyses, we could quantify the influence of cohort and period 
effects on time trends of melanoma death through an examination of the residual deviance 
of models that is the amount of variation in mortality data not explained by a model. 
Analysis of deviance comparing the five classical models (Age, age-drift, age-cohort, age-
period and age-period-cohort) are reported in Table S2. The residual deviance was smaller 
for age-cohort models than for age-period models, indicating that changes in melanoma 
mortality over time were better explained by cohort effects than by period effects. 
Therefore, the remaining of the text will focus on results from age-period-cohort models 
with penalty function applied to the period effect.  
Birth cohort effects can be summarized as the risk to die from melanoma when born at a 
certain year relative to a reference year (1935) for which the risk is arbitrarily set to 1·0 
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(Figure 1ij). Peak years for highest risk of melanoma death were observed in men born 
around 1942 and in women born around 1941. The relative risk of melanoma death of men 
born before 1885 was less than 0·25, i.e., less than 25% the risk of melanoma death of men 
born around 1935. The relative risk of women born before 1885 was 30% the risk of 
melanoma death of women born around 1935. After 1941-42, risks declined without 
interruption. The risk of melanoma death of men and women born around 1990 was similar 
to the risk of men and women born around 1900. 
Because of cohort effects, as time passes, melanoma deaths concentrate in older age groups 
and become steadily rarer in younger age groups (Figure 1kl). Independently from 
population aging, in 1955-59, 30% of melanoma deaths in men occurred before age 50, 40% 
of deaths occurred between 50 and 69, and 30% occurred after 69. From 2005 to 2010, 10% 
of melanoma deaths in men occurred before age 50, 40% of deaths occurred between 50 
and 69, and 50% occurred after 69. Comparable changes were observed in women.  
Results for other regions 
Similarly to Northern Europe, age-adjusted melanoma mortality rates stabilized and then 
declined in subjects less than 50, slowed down or stabilized in subjects 50 to 69, and kept 
rising in subjects 70 years or more (Figure S2). If from 2000 to 2010 annual percent changes 
for all age groups indicated still raising melanoma mortality, principally in Europe (Table S1), 
this was largely due to the demographic weight of older subjects who experienced unabated 
raising trends in melanoma mortality. Hence, trends were mainly explained by cohort 
effects, and with few exceptions, the residual deviance of age-cohort models was smaller 
than that of age-period models (Table S2).  
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Figure 2 shows the lifetime risk of melanoma death for each birth year in a region relative to 
rates in that region observed in the birth cohort centered around 1935. Relative risks are to 
be interpreted for each region, and not between regions. Contrasts in trends between 
regions are the consequence of variations in peak birth years associated with highest risk of 
melanoma death. In all regions, the risk of melanoma death in men was minimal for men 
born before 1880. Then risks sharply increased, reaching a peak for men born in 1940 in 
Oceania, 1943 in North America, 1942 in Northern Europe, 1948 in Western Europe and 
1957 in Central Europe. After peak years, the lifetime risk of dying from melanoma has 
gradually decreased among successive birth years. Of note, age-specific levels and changes 
in melanoma mortality rates in Western and in Central Europe are practically 
superimposable.  
In general, lifetime risk patterns in women resembled to those seen in men, with closeness 
between sexes of birth years for which the risk of melanoma death was highest. In the 
Ireland and United Kingdom region, it took until 1995 before the lifetime risk of melanoma 
death in men came back to risk levels of men born around 1935. In Southern Europe, in both 
sexes, the birth years after which the risk to die from melanoma would decrease have not 
yet been reached, although in women less than 50, first signs of decreases are noticeable in 
recent years (Figure S3). 
As a consequence of cohort effects, in most regions, stabilization and then declines in 
mortality rates progressively extended from younger to older age groups (Figure S3). This 
process is most advanced in Oceania and in North America, where first signs of leveling off 
and declines of rates in subjects more than 69 years of age are perceptible. In these two 
regions, rates have stabilized (men in Oceania) or are declining (women in Oceania and men 
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and women in North America) in all age groups. In Western and Central Europe, stabilization 
and declines in subjects less than 60 are discernible. In Southern Europe, stabilization of 
rates is perceptible over the recent past among subjects less than 50. In Ireland and United 
Kingdom, declines similar to those observed in women less than 50 were not yet visible in 
men of same age, which explains the persistence of a high risk of melanoma death in Irish 
and UK men born after 1953.  
In all regions, independently of aging, melanoma deaths are progressively rarer in younger 
age groups and concentrates in subjects 50 years or more (Figures S4). 
Discussion  
Our study documents that variations in melanoma mortality rates over time were the result 
of substantial changes in the risk of melanoma death in successive generations. If after 2000 
melanoma mortality was still on the rise in some Regions, particularly in Europe, this was 
essentially the consequence of sustained rising trends in older age groups because in 
younger age groups, these trends had stabilized or had started to decline before 1990. Data 
on causes of death are available from 1955 onwards in the WHO mortality database, and 
cohort effects could not be explored for subjects born before 1875. However, probably that 
increasing lifetime risk of melanoma death was already present among subjects born before 
1875[12]. After years of highest risk of melanoma deaths, steady reductions in mortality risks 
took place in successive generations. Over next decades, generations with gradually lower 
risk of lifetime melanoma death will replace generations that had higher lifetime risk of 
melanoma death. We thus expect that in the near future, melanoma mortality will stabilize 
and then decline in all light skinned populations. First signs of declines should be observed in 
Oceania and in Northern America, and lastly in Southern Europe. 
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However, if dying from melanoma is deemed to become a steadily uncommon event in 
younger and middle-aged adults, population aging will keep numbers of patients diagnosed 
with potentially fatal melanoma at a high level over the next two decades because the risk of 
melanoma death in men and women born around 1940 to 1950 is still high. After 2030, 
numbers of melanoma deaths are likely to progressively vanish when subjects born from 
1970 onwards who have a low risk of melanoma death will reach their six or seventh decade 
of life.  
A number of studies already indicated long-term declines in melanoma mortality starting in 
youngest age groups and progressively extending to older age groups. [1, 12-14] The 
principal strengths of our study is the use of data collected over longer periods than in 
previous studies. Also, assembling data by region increased the statistical power, which 
contributed to greater accuracy in estimations of statistical parameters related to age, 
cohort and period effects. Limitations of our study were the absence of usable data for 
France and gaps in mortality data for some years like in the USA. Also, some countries 
brought corrections to their data, which might explain inconsistencies in trends like in 
Central Europe before 1970 (Figure S2f). 
The predominance of cohort effects over period effects we found in our study argues against 
screening and treatment effects. If effective screening or treatment had existed since the 
1980s, their impact on melanoma mortality rates would have affected several age groups at 
about the same time (period effect). Effective treatment exist only since 2010 and are not 
yet associated with long-lasting disease remission [15]. For screening, first effects should 
have been observed in women 30 to 50 because this sex and age group is more inclined to 
attend skin screening. In addition, the purpose of skin screening is to detect melanoma 
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before they have become thick with the possibility of metastases in lymph nodes or in 
distant organs. If skin screening was effective, downward mortality trends should be 
preceded by decreases in the incidence of thick melanoma. However, stable or steady 
increase in the incidence of thick melanoma are observed in virtually all fair-skinned 
populations [3, 7, 16-27]. In subjects less than 50, , trends in thick melanoma are stabilizing 
or increase at a slower pace than in older subjects, but no data suggest declines in incidence 
of thick melanoma that would correlate with stabilization or declines in mortality trends in 
younger age groups [2, 28, 29].  
The predominance of cohort effects points to the knowledge that early life would be the 
most critical period for the occurrence of UV-induced biological events implicated in the 
genesis of melanoma [30]. For instance, migrant studies have documented that the risk of 
melanoma occurrence or of death is two to three times greater among light-skinned subjects 
born in Australia than among subjects of European descent who migrated to Australia after 
15 years [31, 32]. Melanoma risk in adult life seems to be low in the absence of sun exposure 
during childhood [33, 34]. Animal experiments have shown that susceptibility to UV-
induction of melanoma is greatest just after birth [35-37]. According to these data, some 
parallelism should exist between age-specific changes in melanoma incidence and mortality. 
Over the last three decades, increases in the incidence of invasive melanoma have been 
more marked than increases in melanoma mortality. Nonetheless, some evidence has 
recently emerged for stabilisation or decreasing incidence ŝŶŵŽƌĞƌĞĐĞŶƚůǇ ?ďŽƌŶĐŽŚŽƌƚƐŝŶ
Australia, New Zealand, the U.S.A., Canada and Norway [38].  
Taken altogether, these facts indicate that the ultraviolet radiation would be capable to 
cause the occurrence of deadly melanoma in adult life when exposure takes place in early 
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life. We therefore formulate the hypothesis that trends in melanoma mortality would be due 
to dramatic changes in exposure of small children to UV radiation, when in the second part 
of the 19
th
 century, beliefs in the healthiness virtues of the sun and of the ultraviolet 
radiation expanded among health professionals and large segments of the population [12, 
39-41]. The popularity of exposing children to natural or artificial sources of UV would have 
been maximal around 1930 to 1960, depending on regions. The sun spectrum contained 
large amounts of UVA and UVB radiation and many artificial UV-emitting devices 
commercialized before 1960 emitted the full UV range, including the UVC, a highly 
carcinogenic wavelength present in the sunlight but that is completely absorbed by the 
stratospheric ozone layer. At the time, there was complete ignorance about the carcinogenic 
effects of UV radiation. Starting in Oceania in the 1970-80s, sun protection of children has 
become increasingly common with the recognition that sun exposure and sunburn 
experience during childhood causes irreversible damages to the skin and are strong risk 
factors for skin cancer in adult life [42, 43]. So, most probably that UV-exposure patterns of 
children associated with occurrence of deadly melanoma in adults have progressively 
disappeared in successive generations after 1960. However, in Southern Europe, these 
exposure patterns seem to have appeared more recently. 
Long-term data on incidence of advanced melanoma going back to the 1970s and before are 
not available. However, the contrast between trends in the incidence of advanced 
melanoma and of melanoma mortality in younger age groups could be the sign of a gradual 
change in the disease biology, with melanoma being progressively less aggressive as one 
moves away from the peak birth years associated with highest risk of melanoma death. This 
hypothesis is supported by studies that examined the influence of year at diagnosis on risk of 
melanoma death over a fixed duration of follow-up (e.g., 5-year survival) and that took into 
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consideration major predictors of melanoma patient survival. [16, 44, 45] In these studies, 
the more recent the year of diagnosis, the better the survival. One study has suggested that 
vaccination against common infectious diseases in early life was associated with greater 
melanoma survival [46]. One could speculate that increasing vaccination coverage of small 
children after 1950 could have strengthened the immune surveillance of potentially deadly 
melanoma initiated by UV exposures during early life. 
How UV exposure during adulthood affects the risk of melanoma death remains unclear. 
One clue may proceed from Central European countries, where between 1945 and 1989, 
political and economic circumstances have limited possibilities of holidays in sunny climates. 
However, levels and trends in melanoma mortality in Central and in Western Europe were 
quite similar, apart from a 10-year difference in birth cohorts with highest risk of melanoma 
death. These similarities may be an indication that recreational UV exposure during adult life 
has probably little influence on the risk of melanoma death. In contrast, recreational and 
cosmetic UV exposure in adult life, together with increasing skin screening and variability in 
the classification of histologically equivocal lesions would have contributed to most of the 
rising incidence of non-life-threatening in situ or thin invasive melanoma [47-50].  
The strong association between aging and the risk of melanoma death suggests an interplay 
between accumulated sun exposure and the age-related decreasing capability of the 
immune system to control dormant cancer cells having considerable malignant potential 
[51]. Probably that studies in adults should put the emphasis on factors altering the anti-
cancer control functions of the immune system like for instance the UV-induced 
inflammation [52].  
17 
 
In conclusion, over next decades, deaths due to melanoma in light-skinned populations will 
progressively concentrate in oldest subjects, and then progressively diminish for becoming 
an increasingly rare event.  
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Figure captions 
Figure 1  ? Time trends in cutaneous melanoma mortality in Northern Europe, 1955-2010 
(Denmark, Finland, Iceland, Norway, Sweden). Crude numbers of men (1a) and women (1b) 
who died from melanoma. Age-adjusted rates for men (1c) or women (1d) aged less than 50, 
50 to 69, and 70 or more. Age-specific rates for men (1e) or women (1f) by 10-year age 
group. Thick vertical bars indicate years of rate stabilization. Age-specific melanoma 
mortality rate according to year of birth of men (1g) and women (1h). Cumulative lifetime 
risk of melanoma death according to year of birth relative to the risk in men (1i) and women 
(1j) born around 1935. Age-adjusted proportions of melanoma deaths in men (1k) or in 
women (1l) less than 50, 50 to 69, and 70 or more.  
Figure 2 - Cumulative lifetime risk of melanoma death in regions according to year of birth 
relative to the risk in men and women born around 1935. 
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Table S1 Joinpoint regression analysis of time trends of melanoma death after adjustment for age (World standard population).  
APC: annual percent change 
Region Sex Age Trend 1 Trend 2 (if any) Trend 3 (if any) Trend 4 (if any) 
Period APC (95% CI) Period APC (95% CI) Period APC(95% CI) Period APC(95% CI) 
Oceania M All 1955-1985 3.07 [2.77; 3.38] 1985-2006 0.24 [-0.10; 0.59]     
Oceania M <50 1955-1981 1.51 [0.98; 2.05] 1981-2006 -2.23 [-2.75; -1.72]     
Oceania M 50-69 1955-1984 4.03 [3.45; 4.62] 1984-2006 -0.26 [-0.79; 0.27]     
Oceania M  1955-1989 5.39 [4.86; 5.92] 1989-2006 2.70 [2.09; 3.31]     
Oceania F All 1955-1984 1.72 [1.34; 2.11] 1984-2006 -0.50 [-0.94; -0.07]     
Oceania F <50 1955-1984 0.36 [-0.25; 0.98] 1984-2006 -2.42 [-3.30; -1.53]     
Oceania F 50-69 1955-1977 3.53 [2.66; 4.41] 1977-2006 -0.20 [-0.58; 0.18]     
Oceania F  1955-1992 3.35 [2.88; 3.82] 1992-1995 -4.96 [-24.61; 19.83] 1995-2006 3.38 [1.85; 4.94]   
North America M All 1960-1979 3.07 [2.06; 4.08] 1979-1991 1.50 [1.09; 1.92] 1991-2009 -0.29 [-0.48; -0.10]   
North America M <50 1960-1981 1.76 [1.39; 2.12] 1981-1991 -1.31 [-2.19; -0.42] 1991-2009 -2.90 [-3.27; -2.53]   
North America M 50-69 1960-1979 3.87 [2.44; 5.33] 1979-1991 2.02 [1.47; 2.57] 1991-2009 -0.39 [-0.62; -0.15]   
North America M  1960-1994 3.61 [3.39; 3.82] 1994-2009 1.42 [1.06; 1.98]     
North America F All 1960-1983 1.66 [1.47; 1.85] 1983-2009 -0.63 [-0.75; -0.50]     
North America F <50 1960-1984 0.71 [0.45; 0.97] 1984-2009 -2.38 [-2.62; -2.14]     
North America F 50-69 1960-1982 2.28 [1.98; 2.59] 1982-2009 -0.26 [-0.42; -0.10]     
North America F  1960-1994 2.01 [1.81; 2.21] 1994-2009 0.08 [-0.33; 0.49]     
Northern Europe M All 1955-1971 4.69 [3.83; 5.55] 1971-1988 1.97 [1.36; 2.59] 1988-2002 -0.03 [-0.77; 0.71] 2002-2010 2.47 [0.91; 4.05] 
 3 
Region Sex Age Trend 1 Trend 2 (if any) Trend 3 (if any) Trend 4 (if any) 
Period APC (95% CI) Period APC (95% CI) Period APC(95% CI) Period APC(95% CI) 
Northern Europe M <50 1955-1971 5.50 [3.79; 7.25] 1971-2010 -1.34 [-1.73; -0.94]     
Northern Europe M 50-69 1955-1984 3.97 [3.49; 4.46] 1984-2010 0.38 [0.01; 0.74]     
Northern Europe M  1955-2010 3.32 [3.16; 3.48]       
Northern Europe F All 1955-1969 3.74 [2.63; 4.85] 1969-1990 1.40 [0.89; 1.89] 1990-1996 -2.06 [-5.56; 1.56] 1996-2010 1.53 [0.73; 2.34] 
Northern Europe F <50 1955-1970 4.11 [2.32; 5.93] 1970-2010 -0.90 [-1.27; -0.52]     
Northern Europe F 50-69 1955-1983 3.31 [2.80; 3.82] 1983-2010 0.25 [-0.13; 0.64]     
Northern Europe F  1955-2010 2.20 [2.00; 2.39]       
UK & Ireland M All 1955-1993 3.13 [2.95; 3.32] 1993-2010 1.82 [1.48; 2.16]     
UK & Ireland M <50 1955-1985 2.79 [2.31; 3.28] 1985-2010 0.31 [0.73; 0.12]     
UK & Ireland M 50-69 1955-1995 3.67 [3.42; 3.92] 1995-2010 1.43 [0.85; 2.01]     
UK & Ireland M  1955-1976 2.08 [0.86; 3.32] 1976-2010 4.79 [4.53; 5.06]     
UK & Ireland F All 1955-1982 2.98 [2.56; 3.40] 1982-2010 0.50 [0.25; 0.76]     
UK & Ireland F <50 1955-1979 2.36 [1.58; 3.14] 1979-2010 -1.14 [-1.55; -0.73]     
UK & Ireland F 50-69 1955-1981 4.20 [3.55; 4.85] 1981-2010 0.63 [0.30; 0.96]     
UK & Ireland F  1955-1970 1.17 [-0.81; 3.18] 1970-1994 4.22 [3.63; 4.80] 1994-2010 1.62 [0.96; 2.29]   
Western Europe M All 1955-1971 5.73 [4.57; 6.89] 1971-1992 1.84 [1.46; 2.21] 1992-1996 -1.76 [-6.26; 2.95] 1996-2010 1.08 [0.63; 1.52] 
Western Europe M <50 1955-1972 4.92 [3.73; 6.13] 1972-1987 0.39 [-0.40; 1.19] 1987-2010 -1.42 [-1.74; -1.09]   
Western Europe M 50-69 1955-1978 5.13 [4.41; 5.86] 1978-1993 1.54 [0.96; 2.12] 1993-1996 -2.77 [-11.99; 7.42] 1996-2010 1.17 [0.70; 1.63] 
 4 
Region Sex Age Trend 1 Trend 2 (if any) Trend 3 (if any) Trend 4 (if any) 
Period APC (95% CI) Period APC (95% CI) Period APC(95% CI) Period APC(95% CI) 
Western Europe M  1955-1971 6.58 [4.41; 8.79] 1971-1976 -2.73 [-13.33; 9.16] 1976-1991 4.00 [2.98; 5.03] 1991-2010 1.94 [1.57; 2.31] 
Western Europe F All 1955-1970 5.43 [4.10; 6.79] 1970-1991 1.35 [0.95; 1.75] 1991-1998 -1.29 [-3.01; 0.46] 1998-2010 0.83 [0.20; 1.47] 
Western Europe F <50 1955-1970 5.30 [3.53; 7.10] 1970-1993 0.15 [-0.33; 0.64] 1993-1998 -4.58 [-9.54; 0.64] 1998-2010 0.78 [-0.31; 1.88] 
Western Europe F 50-69 1955-1972 5.76 [4.28; 7.26] 1972-1989 1.77 [1.06; 2.48] 1989-1999 -1.01 [-2.17; 0.16] 1999-2010 0.84 [-0.05; 1.73] 
Western Europe F  1955-1993 2.52 [2.14; 2.89] 1993-2010 1.06 [0.59; 1.52]     
Central Europe M All 1961-1970 11.44 [8.21; 14.78] 1970-1981 3.19 [1.59; 4.81] 1981-1987 7.39 [5.14; 9.69] 1987-2010 1.32 [1.16; 1.49] 
Central Europe M <50 1961-1991 4.17 [3.51; 4.83] 1991-2010 -1.19 [-1.85; -0.54]     
Central Europe M 50-69 1961-1970 13.00 [6.62; 19.77] 1970-1989 5.30 [4.24; 6.38] 1989-2010 1.47 [1.19; 1.75]   
Central Europe M  1961-1988 5.35 [4.17; 6.54] 1988-2010 3.00 [2.53; 3.46]     
Central Europe F All 1961-1964 32.84 [5.68; 66.99] 1964-1987 4.17 [3.59; 4.75] 1987-1999 1.63 [0.56; 1.72] 1999-2010 -0.44 [-1.17; 0.30] 
Central Europe F <50 1961-1994 3.53 [2.85; 4.22] 1994-2010 -2.19 [-3.32; -1.04]     
Central Europe F 50-69 1961-1964 39.41 [-1.48; 97.27] 1964-1989 4.29 [3.57; 5.01] 1989-2010 1.07 [0.69; 1.46]   
Central Europe F  1961-1990 4.31 [3.59; 5.02] 1990-2010 1.28 [0.88; 1.69]     
Southern Europe M All 1956-1982 6.28 [5.78; 6.79] 1982-1992 3.48 [2.17; 4.81] 1992-2009 0.91 [0.47; 1.35]   
Southern Europe M <50 1956-1986 4.83 [4.31; 5.34] 1986-2009 -0.09 [-0.59; 0.40]     
Southern Europe M 50-69 1956-1982 6.99 [6.25; 7.74] 1982-1992 3.71 [1.96; 5.49] 1992-2009 0.98 [0.42; 1.53]   
Southern Europe M  1956-1988 6.79 [6.06; 7.52] 1988-2009 2.50 [2.03; 2.96]     
Southern Europe F All 1956-1989 5.28 [4.88; 5.69] 1989-2009 0.35 [-0.12; 0.83]     
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Region Sex Age Trend 1 Trend 2 (if any) Trend 3 (if any) Trend 4 (if any) 
Period APC (95% CI) Period APC (95% CI) Period APC(95% CI) Period APC(95% CI) 
Southern Europe F <50 1956-1959 25.01 [-6.18; 66.56] 1959-1993 3.78 [3.37; 4.20] 1993-2009 -1.17 [-2.05; -0.28]   
Southern Europe F 50-69 1956-1975 4.78 [3.41; 6.16] 1975-1981 9.98 [3.97; 16.35] 1981-1992 2.62 [1.09; 4.18] 1992-2009 0.79 [0.18; 1.39] 
Southern Europe F  1956-1989 6.35 [5.62; 7.07] 1989-2009 0.72 [0.15; 1.28]     
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Table S2 Analysis of deviance for Age-Period-Cohort models 
Region Sex Model Residual degrees of freedom Residual Deviance 
Oceania 
Men 
Age 724 3808.5 
Age-drift 723 2483.0 
Age-Cohort 719 892.6 
Age-Period-Cohort 715 864.0 
Age-Period 719 2296.0 
Age-drift 723 2483.0 
Women 
Age 724 1526.69 
Age-drift 723 1338.10 
Age-Cohort 719 775.96 
Age-Period-Cohort 715 755.60 
Age-Period 719 1254.41 
Age-drift 723 1338.10 
North America 
Men 
Age 560 11964.8 
Age-drift 559 7857.8 
Age-Cohort 555 1492.2 
Age-Period-Cohort 551 1237.1 
Age-Period 555 6567.3 
Age-drift 559 7857.8 
Women 
Age 560 3320.9 
Age-drift 559 3032.0 
Age-Cohort 555 1128.9 
Age-Period-Cohort 551 966.1 
Age-Period 555 2511.1 
Age-drift 559 3032.0 
Northern Europe Men 
Age 799 3698.8 
Age-drift 798 1992.5 
Age-Cohort 794 955.7 
Age-Period-Cohort 790 892.4 
Age-Period 794 1823.3 
Age-drift 798 1992.5 
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Region Sex Model Residual degrees of freedom Residual Deviance 
Women 
Age 799 1909.03 
Age-drift 798 1278.15 
Age-Cohort 794 935.74 
Age-Period-Cohort 790 887.78 
Age-Period 794 1196.94 
Age-drift 798 1278.15 
Ireland and the United Kingdom 
Men 
Age 700 6438.4 
Age-drift 699 1815.5 
Age-Cohort 695 843.1 
Age-Period-Cohort 691 831.1 
Age-Period 695 1780.8 
Age-drift 699 1815.5 
Women 
Age 700 3781.7 
Age-drift 699 1972.0 
Age-Cohort 695 964.0 
Age-Period-Cohort 691 911.3 
Age-Period 695 1780.4 
Age-drift 699 1972.0 
Western Europe 
Men 
Age 799 4314.0 
Age-drift 798 2410.4 
Age-Cohort 794 1248.1 
Age-Period-Cohort 790 1082.3 
Age-Period 794 1980.8 
Age-drift 798 2410.4 
Women 
Age 799 2433.1 
Age-drift 798 1745.5 
Age-Cohort 794 1361.2 
Age-Period-Cohort 790 1083.1 
Age-Period 794 1369.0 
Age-drift 798 1745.5 
Central Europe Men Age 559 4099.8 
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Region Sex Model Residual degrees of freedom Residual Deviance 
Age-drift 558 1537.4 
Age-Cohort 554 914.6 
Age-Period-Cohort 550 701.8 
Age-Period 554 1162.0 
Age-drift 558 1537.4 
Women 
Age 559 2572.76 
Age-drift 558 1188.98 
Age-Cohort 554 941.74 
Age-Period-Cohort 550 643.74 
Age-Period 554 818.22 
Age-drift 558 1188.98 
Southern Europe 
Men 
Age 740 9604.2 
Age-drift 739 2241.2 
Age-Cohort 735 1350.4 
Age-Period-Cohort 731 922.8 
Age-Period 735 1453.8 
Age-drift 739 2241.2 
Women 
Age 740 6574.7 
Age-drift 739 1956.0 
Age-Cohort 735 1566.5 
Age-Period-Cohort 731 963.9 
Age-Period 735 1057.8 
Age-drift 739 1956.0 
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Figure S1a: Absolute numbers RIPHODQRPDGHDWKVE\DJHWRLQ2FHDQLD 
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Figure S1b$EVROXWHQXPEHUVRIPHODQRPDGHDWKVE\DJHWRLQ1RUWK$PHULFD 
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Figure S1c$EVROXWHQXPEHUVRIPHODQRPDGHDWKVE\DJHWRLQ1RUWKHUQ(XURSH 
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Figure S1d: Absolute numbers of melanoma deaths by age (<50; 50 to LQ,UHODQGDQG8QLWHG.LQJGRP 
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Figure S1e$EVROXWHQXPEHUVRIPHODQRPDGHDWKVE\DJHWRLQWestern Europe 
 
Note: the sudden increase of 1980 in Western Europe was due to the introduction of mortality data of the former German Federal Republic (GFR) and the German 
Democratic Republic (GDR). Mortality data in the Germany (GDR and GFR) did not exist before 1980.    
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Figure S1f$EVROXWHQXPEHUVRIPHODQRPDGHDWKVE\DJHWRLQ&HQWUDO(XURSH 
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Figure S1g$EVROXWHQXPEHUVRIPHODQRPDGHDWKVE\DJHWRLQSouthern Europe  
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Figure S2aPHODQRPDPRUWDOLW\E\DJHWRDQGMRLQSRLQWPRGHOOLQJLQ Oceania 
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Figure S2bPHODQRPDPRUWDOLW\E\DJHWRDQGjoinpoint modelling in North America 
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Figure S2cPHODQRPDPRUWDOLW\E\DJHWRDQGMRLQSRLQWPRGHOOLQJLQ1RUWKHUQ(XURSH 
 
  
 19 
Figure S2dPHODQRPDPRUWDOLW\E\DJHWRDQGMRLQSRLQWPRGHOOLQJLQ,UHODQGDQG8QLWHGKingdom 
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Figure S2ePHODQRPDPRUWDOLW\E\DJHWRDQGMRLQSRLQWPRGHOOLQJLQ:HVWHUQ(XURSH 
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Figure S2fPHODQRPDPRUWDOLW\E\DJHWRDQGMRLQSRLQWPRGHOOLQJLQ&HQWUDO(XURSH 
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Figure S2g: melanoma mortality by DJHWRDQGMRLQSRLQWPRGHOOLQJin Southern Europe 
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Figure S3a: Age-specific mortality rates by birth cohorts in Oceania 
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Figure S3b: Age-specific mortality rates by birth cohorts in North America 
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Figure S3c: Age-specific mortality rates by birth cohorts in Northern Europe 
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Figure S3d: Age-specific mortality rates by birth cohorts in Ireland and United Kingdom 
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Figure S3e: Age-specific mortality rates by birth cohorts in Western Europe 
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Figure S3f: Age-specific mortality rates by birth cohorts in Central Europe 
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Figure S3g: Age-specific mortality rates by birth cohorts in Southern Europe 
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Figure S4a: Age-adjusted proportions of melanoma deaths by DJHWRLQOceania 
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Figure S4b: Age-DGMXVWHGSURSRUWLRQVRIPHODQRPDGHDWKVE\DJHWRLQ1RUWK$PHULFD 
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Figure S4c: Age-DGMXVWHGSURSRUWLRQVRIPHODQRPDGHDWKVE\DJHWRLQ1RUWKHUQ(XURSH 
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Figure S4d: Age-adjusted proportions of melanoma deDWKVE\DJHWRLQ,UHODQGDQG8QLWHG.LQJGRP 
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Figure S4e: Age-DGMXVWHGSURSRUWLRQVRIPHODQRPDGHDWKVE\DJHWRLQ:HVWHUQ(XURSH 
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Figure S4f: Age-adjusted proportions of melanoma deaths by age (<WRLQ&HQWUDO(XURSH 
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Figure S4g: Age-DGMXVWHGSURSRUWLRQVRIPHODQRPDGHDWKVE\DJHWRLQ6RXWKHUQ(XURSH 
 
